ShangPharma (SHP -2.4%) slips after missing on its Q2 results earlier today. The company also reconfirms its guidance for net revenues for FY12. Net revenues are expected to be approximately $131.7 to $136.2 million, which represents growth of approximately 18% to 22% compared with FY11. William Blair cuts the shares to Market Perform on the report.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs